Dr Hoehn earned his M.D. and PhD in neuroscience from Stanford University and trained in Neurosurgery at the University of Virginia. Later, he completed a neurosurgical fellowship/Visiting Professorship at Dongguk University, Korea.

Most recently, Dr Hoehn joined Blue Rock Therapeutics as VP of Neurology, overseeing Parkinsons phase 3 cell therapy trial, and several IND enabling cell lines in Jan 2026. He has over 15 years of in-depth experience in the biopharmaceutical and medical device industry, including global research and development, clinical operations, business development, and consulting, having spent time working for companies in Asia Pacific, Europe, and North America, as well as starting his own consulting business, Neuroaxs LLC. Having trained as a neurosurgeon prior to entering industry, Dr. Hoehn has focused on interventions into acute and chronic neurodegenerative diseases such as Stroke, ALS, GBS, Alzheimer's, Parkinson’s and Huntington's diseases.

While at Kyowa Kirin, he was involved in the development and successful launch of Istradefylline in the United States, the first novel therapy for Parkinson’s in over 15 years. He previously served as CMO for Johnson and Johnson Codman Neuro division, and global lead for Clinical Development at UCB. It was at UCB that Dr. Hoehn began his work with complement inhibitors, leading the Zilucoplan mission, which included Myasthenia gravis, IMNM, and ALS. Which drove his work at Annexon with complement-based therapies, leading clinic development for ALS, Huntington's Disease, and GBS indications. His recent move to Blue Rock has allowed him to bring all of his training in device, pharma, surgery to bare on the world’s most advance cell therapy program in Parkinson’s disease. Additionally, through his consulting company, he is active in work with digital therapeutics, siRNA, AVV gene therapy, and stroke-based therapy companies.

Read more